CLL-1 is an interesting antigen for targeted therapy since it is highly expressed on AML blasts and LSCs, which are the cells responsible for relapsing malignancy and driving disease recurrence [57]. This evidence concerns the gene CLEC12A and acute myeloid leukemia.